MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events
Authors:
- 6 March 2023
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (4) , 1-17
Abstract
Background Approximately 18% of patients with cancer use cannabis at one time as palliation or treatment for their cancer. We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients. Methods A systematic review of randomized trials with or without meta-analysis was carried out from MEDLINE, CCTR, Embase, and PsychINFO. The search involved randomized trials of cannabis in cancer patients. The search ended on November 12, 2021. The Jadad grading system was used for grading quality. Inclusion criteria for articles were randomized trials or systematic reviews of randomized trials of cannabinoids versus either placebo or active comparator explicitly in adult patients with cancer. Results Thirty-four systematic reviews and randomized trials met the eligibility criteria for cancer pain. Seven were randomized trials involving patients with cancer pain. Two trials had positive primary endpoints, which could not be reproduced in similarly designed trials. High-quality systematic reviews with meta-analyses found little evidence that cannabinoids are an effective adjuvant or analgesic to cancer pain. Seven systematic reviews and randomized trials related to harms and adverse events were included. There was inconsistent evidence about the types and levels of harm patients may experience when using cannabinoids. Conclusion The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.Keywords
This publication has 80 references indexed in Scilit:
- Interactions between μ-Opioid Receptor Agonists and Cannabinoid Receptor Agonists in Rhesus Monkeys: Antinociception, Drug Discrimination, and Drug Self-AdministrationThe Journal of Pharmacology and Experimental Therapeutics, 2013
- Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose TrialThe Journal of Pain, 2012
- Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy‐induced nausea and vomitingBritish Journal of Clinical Pharmacology, 2010
- Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related PainJournal of Pain and Symptom Management, 2010
- Use of Causal Language in Observational Studies of Obesity and NutritionObesity Facts, 2010
- Why Most Discovered True Associations Are InflatedEpidemiology, 2008
- Industry funding and the reporting quality of large long-term weight loss trialsInternational Journal of Obesity, 2008
- Interactions between Δ9-tetrahydrocannabinol and μ opioid receptor agonists in rhesus monkeys: discrimination and antinociceptionPsychopharmacology, 2008
- Cannabinoid Receptor as a Novel Target for the Treatment of Prostate CancerCancer Research, 2005
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996